The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitising or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorder which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.

The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitising or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorder which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.

The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitising or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorder which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.

The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumors. The invention also relates to methods of treating tumours using said compositions. The invention discloses that following intratumoral injection of α-Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoural α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumour cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumour specific T cells thereby converting the treated tumour lesions into in situ autologous tumour vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumour resection. In addition to the regression and/or destruction of the treated tumour, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumour. The invention further teaches the enhancement of anti-tumour α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules.

The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumors. The invention also relates to methods of treating tumours using said compositions. The invention discloses that following intratumoral injection of α-Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoural α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumour cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumour specific T cells thereby converting the treated tumour lesions into in situ autologous tumour vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumour resection. In addition to the regression and/or destruction of the treated tumour, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumour. The invention further teaches the enhancement of anti-tumour α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules.

The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules.

The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules.

The present invention relates to methods of treating Lewy body dementia, multi-system atrophy or pure autonomic failure in a subject in need thereof. Also provided are compositions for treating Lewy body dementia, multi-system atrophy or pure autonomic failure.

The present invention relates to methods of treating Lewy body dementia, multi-system atrophy or pure autonomic failure in a subject in need thereof. Also provided are compositions for treating Lewy body dementia, multi-system atrophy or pure autonomic failure.

There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.